HCV infection, B-cell non-Hodgkin’s lymphoma and immunochemotherapy: Evidence and open questions

Table 1 Features and outcome of hepatitis C virus + patients with aggressive B-cell non-Hodgkin’s lymphoma treated with chemotherapy and immunochemotherapy

Author	Year	HCV + patients1	Histology	Study	Therapy	Severe HT (%)	Poor prognostic factors	ORR (%)	PFS	OS
Visco et al[6]	2006	132	DLBCL	Multicenter, retrospective	CHOP-like (85%)	15	Hepatic dysfunction	93	51% (5 yr)	72% (5 yr)
					R-CHOP-like (26%)		HBV co-infection
							High IPI
							Advanced stage
							Nodal origin
Besson et al[13]	2006	26	DLBCL	Case control, retrospective	Intensified CHT, no Rituximab	45	Advanced stage	72	-	56% (5 yr)
							High IPI
Arcaini et al[9]	2010	101	DLBCL	Retrospective series	CHOP-like	15	HCV genotype 1	77	43% (5 yr)	68% (5 yr)
					R-CHOP-like (23%)		HT during CHT
Marignani et al[10]	2011	8	DLBCL = 7	Retrospective series	R-CHOP-like	28	NE	80	70% (4 yr)	80% (4 yr)
			BL = 1
Ennishi et al[11]	2010	131	DLBCL	Retrospective series	R-CHOP-like	27	Hepatic dysfunction	-	69% (3 yr)	75% (3 yr)
							Age
							High IPI
							Advanced stage

¹Number of hepatitis C virus (HCV) + patients treated with curative intent. NE: Not evaluable; PFS: Progression-free survival; OS: Overall survival; HT: Hepatic toxicity; CHT: Chemotherapy; IPI: International Prognostic Index.

Table 2 Clinical features and prevalence of hepatitis C virus-positive patients in low grade B-lymphoma series

Author	Year	HCV-positive patients number	Histology	Study type	Clinical features of HCV-positive1
Arcaini et al[19]	2006	49 (15%) out of 309	SMZL	Retrospective series analysis	B-symptoms
					Female prevalence
					Abdominal lymph nodes
					Villous lymphocytes
					Monoclonal component
					Cryoglobulin
Ferreri et al[12]	2006	7 (12%) out of 55	OAL of the MALT type	Retrospective series analysis	Advanced extra-orbital disease
					Lymph node dissemination
					Involvement of other extranodal organs
					Worse progression free survival
Arcaini et al[23]	2007	9 (19%) out of 47	Nodal MZL	Retrospective series analysis	Advanced stage
					B-symptoms
					Cryoglobulin
Arcaini et al[30]	2006	60 (35%) out of 172	Non-gastric MALT	Retrospective series analysis	Single MALT site
					Older age
					Female prevalence
					Less frequent marrow involvement
Strianese et al[24]	2010	23 (18%) out of 129	OAL	Retrospective series analysis	More widespread disease at the onset

¹Clinical features with statistical relevance compared to hepatitis C virus (HCV)-negative patients. OAL: Ocular adnexal lymphoma; MZL: Marginal zone lymphoma; SMZL: Splenic MZL.